Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 9/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | IL1RN | P18510 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569493 | 0.88 | NPC1 (0.54) | NPC1RAB9ADPP4DPP8DPP9 | |
| SCHEMBL14557769 | 0.87 | NPC1 (0.49) | NPC1RAB9ADPP4DPP8DPP9 | |
| SCHEMBL14557764 | 0.78 | APEX1 (0.42) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL26997900 | 0.73 | SMN1; SMN2 (0.44) | NPC1RAB9ADPP4DPP8DPP9 | |
| SCHEMBL26724937 | 0.72 | SMN1; SMN2 (0.49) | NPC1RAB9ADPP4DPP8MAPT | |
| SCHEMBL19432460 | 0.72 | SMN1; SMN2 (0.49) | NPC1RAB9ADPP4DPP8MAPT | |
| SCHEMBL14557864 | 0.72 | STAT6 (0.41) | DPP4DPP8DPP9DPP7KMT2A | |
| SCHEMBL26734026 | 0.72 | SMN1; SMN2 (0.42) | NPC1RAB9ADPP4DPP8DPP9 | |
| SCHEMBL14557874 | 0.71 | DPP4 (0.40) | DPP4DPP8DPP9DPP7MAPT | |
| SCHEMBL5416488 | 0.71 | AKR1C3 (0.51) | MAPTIL1RNKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | NPC1 3300/4885RAB9A 1984/4885DPP4 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.